1. 1246PDTalimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study. (23rd October 2018) Authors: Gogas, H; Samoylenko, I; Schadendorf, D; Gutzmer, R; Grob, J J; Sacco, J J; Gorski, K; Anderson, A; Liu, C; Malvehy, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 47O Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice. (15th December 2019) Authors: Drakaki, A; Luhn, P; Wakelee, H; Dhillon, P K; Kent, M; Shim, J; Degaonkar, V; Hoang, T; McNally, V; Chui, S Y; Gutzmer, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 60PResponse rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials. (17th December 2018) Authors: Gogas, H; Gutzmer, R; Malvehy, J; Mehnert, J M; Liu, K; Pickett, C A; Snyder, W; Chesney, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Profiling of histamine H4 receptor agonists in native human monocytes. (15th August 2013) Authors: Gschwandtner, M; Koether, B; Werfel, T; Stark, H; Gutzmer, R Journal: British journal of pharmacology Issue: Volume 170:Number 1(2013:Sep.) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The effect of mogamulizumab on the malignant T cell population: a monocentric retrospective analysis. (September 2022) Authors: Gosmann, JG; Bielefeld, A; Schaper-Gerhardt, K; Gutzmer, R; Stadler, R Journal: European journal of cancer Issue: Volume 173(2022)Supplement 1 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗